The bill is re-introduced in the House for the 118th Congress by co-leads Representatives Glenn Grothman (R-WI), Suzanne Bonamici (D-OR), Gus Bilirakis (R-FL), Joe Morelle (D-NY), Brian Fitzpatrick (R-PA), Brian Higgins (D-NY), and Doris Matsui (D-CA). See press release from International Myeloma Foundation that includes a quote from AACI.

The bill is re-introduced for the 118th Congress in the Senate by Senators Tina Smith (D-MN) and Jerry Moran (R-KS). See the one pager on the bill here. See the Coalition to Improve Access to Cancer Care (CIACC) press release here.

AACI, as part of the Coalition to Improve Access to Cancer Care (CIACC), signed on to a letter to President Biden and Vice President Harris calling on the administration to include the Cancer Drug Parity Act as a part of its "Cancer Moonshot 2.0".

The bill is re-introduced in the Senate led by Senators Tina Smith (D-MN) and Jerry Moran (R-KS).

Introduced in the House. (117th Congress)

AACI, as part of the Coalition to Improve Access to Cancer Care (CIACC), signed on to a letter to United States Health and Human Services (HHS) Secretary Alexander Azar asking the administration to consider the Cancer Drug Parity Act as part of their Executive Order on Improving Rural Health and Telehealth Access.

AACI, as part of the Coalition to Improve Access to Cancer Care (CIACC), signed on to a letter to Senator Lamar Alexander (R-TN), chairman of the Senate Health, Education, Labor and Pensions (HELP) committee to recommend the Cancer Drug Parity Act for consideration as the committee drafts their "Preparing for the Next Pandemic" whitepaper.

Rep. Brian Higgins (D-NY) and bill co-signers Rep. Gus Bilirakis (R-FL), Rep. Brett Guthrie (R-KY), and Rep. Doris Matsui (D-CA), sent a letter to the House urging them to consider including the Cancer Drug Parity Act in the next COVID-19 response package.

On April 23, 2020, a letter led by Senator Tina Smith (D-MN) co-signed by 13 other senators was sent to Hill leadership urging them to consider including the Cancer Drug Parity Act in the next COVID-19 response package.

The Association of American Cancer Institutes (AACI) officially signs on to a letter in support of the legislation.